Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tongbi Tuomin Gao is a topical herbal formulation widely utilized in China for the symptomatic relief of allergic rhinitis, chronic rhinitis, and nasal congestion. The product typically functions through a combination of aromatic compounds and Traditional Chinese Medicine (TCM) extracts. Key active ingredients often include menthol and camphor, which act on TRPM8 and TRPV1 receptors to provide a cooling sensation and alleviate the perception of airflow obstruction. Additionally, botanical components such as *Magnolia biondii* (Xin Yi), *Xanthium sibiricum* (Cang Er Zi), and *Centipeda minima* (E Bu Shi Cao) are included for their purported anti-inflammatory and anti-allergic properties, potentially inhibiting mast cell degranulation and local histamine release. While frequently marketed as a medical device or health product (sanitation grade) by companies like Renhe and Xiuzheng, it remains a staple in the management of minor upper respiratory allergies and congestion in the region.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Tongbi Tuomin Gao.